AAAP (ACNU, adriamycin, methotrexate, prednisolone) therapy for adult erythroleukemia.
A new quadruple combination chemotherapy for acute leukemia with ACNU, Adriamycin, methotrexate, and prednisolone was developed and codenamed AAAP in 1978. We have obtained excellent chemotherapeutic results with AAAP for conventional chemotherapy-resistant leukemia in Japan. Recently we have treated three adults with erythroleukemia with an AAAP regimen. In Case I, a 45-year-old woman attained a complete remission after only one course of AAAP, which was maintained for 21 months. The patient has been alive for over 32 months. In Case 2, a 52-year-old woman, and Case 3, a 38-year-old man, a complete remission was achieved after two courses of AAAP. Both patients have been alive over 21 and 13 months, respectively, with an initial remission duration of 14 months and 11+ months respectively. We conclude that AAAP therapy would be useful for remission induction of erythroleukemia.
D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols; D001772:Blood Cell Count; D001853:Bone Marrow / Q000648:ultrastructure; D004317:Doxorubicin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D004920:Erythropoiesis; D005260:Female; D006801:Humans; D004915:Leukemia, Erythroblastic, Acute / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D015376:Nimustine; D009607:Nitrosourea Compounds / Q000008:administration & dosage; D011239:Prednisolone / Q000008:administration & dosage; D013997:Time Factors
D000970:Antineoplastic Agents; D009607:Nitrosourea Compounds; D015376:Nimustine; D004317:Doxorubicin; D011239:Prednisolone; D008727:Methotrexate